Trial reportNeurology2017
Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.
Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01952288 (Simvastatin), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- The effects of cholesterol-lowering drugs on neurocognitive function: systematic review and meta analysis.Frontiers in neurologyPooled it
- Are Hippocampal Hypoperfusion and ATP Depletion Prime Movers in the Genesis of Alzheimer's Disease? A Review of Recent Pertinent Observations from Molecular Biology.International journal of molecular sciences · 2025Review
- Alzheimer's Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective.International journal of molecular sciences · 2025Review
- Mechanisms of interventions targeting modifiable factors for dementia risk reduction.Molecular neurodegeneration · 2025Review
- Amyloid-beta metabolism in age-related neurocardiovascular diseases.European heart journal · 2025Review
- Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence.Current atherosclerosis reports · 2024Review
- Alzheimer's Disease-Related Epigenetic Changes: Novel Therapeutic Targets.Molecular neurobiology · 2024Review
- New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer's disease.Frontiers in neuroscience · 2024Review
- Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer's Disease.International journal of molecular sciences · 2023Review
- Does statin use affect amyloid beta deposition and brain metabolism?CNS neuroscience & therapeutics · 2023Article
- Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise.The FEBS journal · 2023Review
- Markers of Cerebrovascular Injury, Inflammation, and Plasma Lipids Are Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Cognitively Normal Persons.Journal of Alzheimer's disease : JAD · 2022Article
- Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment.International journal of molecular sciences · 2021Review
- Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies.Clinical and translational medicine · 2021Review
- Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain.Frontiers in neuroinformatics · 2021Review
- Amyloid-β-independent regulators of tau pathology in Alzheimer disease.Nature reviews. Neuroscience · 2020Review
- Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk.PloS one · 2020Article
- Modifiable Risk Factors for Alzheimer's Disease.Frontiers in aging neuroscience · 2019Article
- Simvastatin reduces circulating oxysterol levels in men with hypercholesterolaemia.Redox biology · 2018Article
- Metabolic Syndrome and Neuroprotection.Frontiers in neuroscience · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Ge LiFrom the Geriatric Research, Education, and Clinical Center (G.L., W.H.R.) and Northwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (G.L., C.L.M., D.M., S.P.M., E.C.P., M.A.R., E.R.P.), Veterans Affairs Puget Sound Health Care System; Departments of Psychiatry and Behavioral Sciences (G.L., E.C.P., M.C., M.A.R., E.R.P.) and Medicine (W.H.R.), University of Washington, Seattle; and Department of Neurology (A.M.F.), Washington University in St. Louis, MO. gli@uw.edu.
Cynthia L MayerFrom the Geriatric Research, Education, and Clinical Center (G.L., W.H.R.) and Northwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (G.L., C.L.M., D.M., S.P.M., E.C.P., M.A.R., E.R.P.), Veterans Affairs Puget Sound Health Care System; Departments of Psychiatry and Behavioral Sciences (G.L., E.C.P., M.C., M.A.R., E.R.P.) and Medicine (W.H.R.), University of Washington, Seattle; and Department of Neurology (A.M.F.), Washington University in St. Louis, MO.
Daniel MorelliFrom the Geriatric Research, Education, and Clinical Center (G.L., W.H.R.) and Northwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (G.L., C.L.M., D.M., S.P.M., E.C.P., M.A.R., E.R.P.), Veterans Affairs Puget Sound Health Care System; Departments of Psychiatry and Behavioral Sciences (G.L., E.C.P., M.C., M.A.R., E.R.P.) and Medicine (W.H.R.), University of Washington, Seattle; and Department of Neurology (A.M.F.), Washington University in St. Louis, MO.
Steven P MillardFrom the Geriatric Research, Education, and Clinical Center (G.L., W.H.R.) and Northwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (G.L., C.L.M., D.M., S.P.M., E.C.P., M.A.R., E.R.P.), Veterans Affairs Puget Sound Health Care System; Departments of Psychiatry and Behavioral Sciences (G.L., E.C.P., M.C., M.A.R., E.R.P.) and Medicine (W.H.R.), University of Washington, Seattle; and Department of Neurology (A.M.F.), Washington University in St. Louis, MO.
Wendy H RaskindFrom the Geriatric Research, Education, and Clinical Center (G.L., W.H.R.) and Northwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (G.L., C.L.M., D.M., S.P.M., E.C.P., M.A.R., E.R.P.), Veterans Affairs Puget Sound Health Care System; Departments of Psychiatry and Behavioral Sciences (G.L., E.C.P., M.C., M.A.R., E.R.P.) and Medicine (W.H.R.), University of Washington, Seattle; and Department of Neurology (A.M.F.), Washington University in St. Louis, MO.
Eric C PetrieFrom the Geriatric Research, Education, and Clinical Center (G.L., W.H.R.) and Northwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (G.L., C.L.M., D.M., S.P.M., E.C.P., M.A.R., E.R.P.), Veterans Affairs Puget Sound Health Care System; Departments of Psychiatry and Behavioral Sciences (G.L., E.C.P., M.C., M.A.R., E.R.P.) and Medicine (W.H.R.), University of Washington, Seattle; and Department of Neurology (A.M.F.), Washington University in St. Louis, MO.
Monique CherrierFrom the Geriatric Research, Education, and Clinical Center (G.L., W.H.R.) and Northwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (G.L., C.L.M., D.M., S.P.M., E.C.P., M.A.R., E.R.P.), Veterans Affairs Puget Sound Health Care System; Departments of Psychiatry and Behavioral Sciences (G.L., E.C.P., M.C., M.A.R., E.R.P.) and Medicine (W.H.R.), University of Washington, Seattle; and Department of Neurology (A.M.F.), Washington University in St. Louis, MO.
Anne M FaganFrom the Geriatric Research, Education, and Clinical Center (G.L., W.H.R.) and Northwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (G.L., C.L.M., D.M., S.P.M., E.C.P., M.A.R., E.R.P.), Veterans Affairs Puget Sound Health Care System; Departments of Psychiatry and Behavioral Sciences (G.L., E.C.P., M.C., M.A.R., E.R.P.) and Medicine (W.H.R.), University of Washington, Seattle; and Department of Neurology (A.M.F.), Washington University in St. Louis, MO.
Murray A RaskindFrom the Geriatric Research, Education, and Clinical Center (G.L., W.H.R.) and Northwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (G.L., C.L.M., D.M., S.P.M., E.C.P., M.A.R., E.R.P.), Veterans Affairs Puget Sound Health Care System; Departments of Psychiatry and Behavioral Sciences (G.L., E.C.P., M.C., M.A.R., E.R.P.) and Medicine (W.H.R.), University of Washington, Seattle; and Department of Neurology (A.M.F.), Washington University in St. Louis, MO.
Elaine R PeskindFrom the Geriatric Research, Education, and Clinical Center (G.L., W.H.R.) and Northwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (G.L., C.L.M., D.M., S.P.M., E.C.P., M.A.R., E.R.P.), Veterans Affairs Puget Sound Health Care System; Departments of Psychiatry and Behavioral Sciences (G.L., E.C.P., M.C., M.A.R., E.R.P.) and Medicine (W.H.R.), University of Washington, Seattle; and Department of Neurology (A.M.F.), Washington University in St. Louis, MO.
University of Washington · US
Funding
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2MThe natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5MEffects of Simvastatin on CSF AD biomarkers in cognitively normal subjectsR01AG033693 · NIA · UNIVERSITY OF WASHINGTON · PI LI, GAIL · 2009 to 2011
$1.4MNIA NIH HHS P01 AG026276NIA NIH HHS P50 AG005136NIA NIH HHS R01 AG033693
Abstract
objectiveTo examine potential disease-modifying effects of statin drugs, we conducted a 12-month randomized, placebo-controlled clinical trial of simvastatin in cognitively normal adults using change in CSF Alzheimer disease biomarkers as primary outcome measure.
methodsParticipants were 45-64 years old and statin-naive with normal cognition and normal or mildly elevated cholesterol. Forty-six participants completed the 1-year study per protocol (25 in the simvastatin and 21 in the placebo group). Simvastatin was titrated to 40 mg/d. CSF Aβ
resultsChanges from baseline did not differ significantly between treatment groups for any CSF biomarker, with
conclusionsSimvastatin-related reductions in CSF p-tau
Indexed as
Outcome Assessment, Health CareAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersCholesterol, LDLFemaleFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPeptide FragmentsSimvastatintau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsPeptide FragmentsSimvastatintau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT01952288ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.